The drug major had inherited the facility as part of its acquisition of Ranbaxy in 2015
The stock moved higher by 7% to Rs 729 on the NSE on back of heavy volumes.
Halol plant is key for Sun Pharma and contributed in high single digits to its US sales
The stock declined by 4.25% to end at Rs 622.50 on BSE. Intra-day, it lost 4.47% to Rs 621.05
Sun also said sales in its emerging markets rose 14% and those in the rest of the world were up 33%
Delhi High Court allows companies to approach bench after IPAB order
US market makes up half of Sun's revenue but business faces huge price erosion, regulatory issues
Seciera is a patented, proprietary nanomicellar formulation of cyclosporine
Product acquisition gains partly offset losses because of pricing collusion probe in the US
Sun Pharmaceutical was approved by the US drug regulator in July 2015
The transaction gives Sun Pharma its first branded oncology product
SPARC was up 4% at Rs 320, while Sun Pharma up 1% at Rs 622 on the BSE, against 0.39% fall in Sensex at 09:27 am
The stock dipped 2% to Rs 615 on the BSE, its lowest level since November 9, 2016
Credit Suisse cuts FY18 profit estimate by 5%
The violations listed by the FDA after its latest inspection at Halol include problems with Sun's quality control system
US FDA inspected the facility from November 17-December 1, 2016
The company said none of the nine observations were characterized by the USFDA as repeat observations
The Halol plant is a key manufacturing unit for Sun Pharma, which earns about half its revenue from the US market
It is unclear what violations the FDA found; Sun did not disclose them
The stock was down 5% after the company confirms that Halol facility has undergone an inspection by USFDA